Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2003-05-21
2009-02-10
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S300000, C536S023100
Reexamination Certificate
active
07488809
ABSTRACT:
The invention pertains to methods for using chimeric polypeptides of the formula:in-line-formulae description="In-line Formulae" end="lead"?B—Xin-line-formulae description="In-line Formulae" end="tail"?wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B—X are also included.
REFERENCES:
patent: 5198344 (1993-03-01), Croop et al.
patent: 5338839 (1994-08-01), McKay et al.
patent: 5350890 (1994-09-01), Fairbrother et al.
patent: 5747028 (1998-05-01), Calderwood et al.
patent: 5763165 (1998-06-01), Boon-Falleur et al.
patent: 5980898 (1999-11-01), Glenn et al.
patent: 6197299 (2001-03-01), Dohlsten
patent: 6482586 (2002-11-01), Arab et al.
patent: 130132 (1985-01-01), None
patent: 439 954 (1991-08-01), None
patent: 532090 (1993-03-01), None
patent: 739984 (1996-10-01), None
patent: WO 91/09871 (1991-07-01), None
patent: WO 93/16186 (1993-08-01), None
patent: WO 93/17115 (1993-09-01), None
patent: WO 95/14085 (1995-05-01), None
patent: WO 95/14085 (1995-05-01), None
patent: WO 96/16178 (1996-05-01), None
patent: WO 97/13410 (1997-04-01), None
patent: WO 98/11229 (1998-03-01), None
patent: WO 99/59627 (1999-11-01), None
patent: WO 99/59627 (1999-11-01), None
Definition of “specific” on Merriam-Wester Online downloaded on Aug. 2, 2005.
Rimoldi et al., Int J Cancer. Sep. 9, 1999;82(6):901-7.
Chang et al., Gynecol Oncol. May 2005;97(2):342-7.
Cohen et al., The Journal of Immunology, 2003, 170: 4349-4361.
Fominaya et al., J. Biol. Chem., 1996, vol. 271, pp. 10560-10568.
Allinquant et al. “Downregulation of Amyloid Precursor Protein Inhibits Neurite Outgrowth In Vitro.”J. Cell Biol. 1995;128(5):919-27.
Austyn. “New insights into the mobilization and phagocytic activity of dendritic cells.”J Exp Med. Apr. 1, 1996;183(4):1287-92.
Boël et al. “BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes.”Immunite1995;2:167-75.
Boon “Toward a genetic analysis of tumor rejection antigens.”Adv Cancer Res. 1992;58:177-210.
Bos “The skin as an organ of immunity.”Clin Exp Immunol. Jan. 1997;107 Suppl 1:3-5.
Bower et al. “Cloning and Characterization of theBacillus subtilis birA Gene Encoding a Repressor of the Biotin Operon.”J. Bacteriology1995;177(9):2572-75.
Brichard et al. “The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas.”J. Exp. Med. 1993;178:489-95.
Calderwood et al. “Nucleotide sequence of the Shiga-like toxin genes ofEscherichia coli.” Proc. Natl. Acad. Sci. USA1987;84(13):4364-68.
Cella et al. “Origin, maturation and antigen presenting function of dendritic cells.”Curr Opin Immunol. Feb. 1997;9(1):10-6.
Chicz et al. “Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development.”Immunol. Today1994;15(4):155-60.
Ciernik et al. “Mutant Oncopeptide Immunization Induces CTL Specifically Lysing Tumor Cells Endogenously Expressing the Corresponding Intact Mutant p53.”Hybridoma1995;14:139-42.
Coulie et al. “A New Gene Coding for a Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas.”J. Exp. Med. 1994;180:35-42.
Curti “Physical barriers to drug delivery in tumors.”Crit Rev Oncol Hematol. Feb. 1993;14(1):29-39.
Davis et al. “DNA-Mediated Immunization in Mice Induces a Potent MHC Class I-Restricted Cyto-toxic T Lymphocyte Response to the Hepatitis B Envelope Protein.”Hum. Gene Therapy1995;6:1447-56.
De Plaen et al. “Structure, chromosomal localization, and expression of 12 genes of theMAGEfamily.”Immunogenetics1994;40:360-69.
Edelman “Vaccine adjuvants.”Rev Infect Dis. May-Jun. 1980;2(3):370-83.
Ezzell “Cancer ‘vaccines’: An idea whose time has come?”J. NIH Res. 1995;7:46-9.
Feltkamp et al. “Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.”Eur J Immunol. Sep. 1995;25(9):2638-42.
Feltkamp et al. “Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.”Eur. J. Immunol. 1993;23:2242-9.
Flørenes et al. “Expression of the neuroectodermal intermediate filament nestin in human melanomas.”Cancer Res. Jan. 15, 1994;54(2):354-6.
Furukawa et al. “Clonal Expansion of CD8+Cytotoxic T Lymphocytes against Human T Cell Lymphotrophic Virus Type I (HTLV-I) Genome Products in HTLV-I-associated Myelopathy/Tropical Spastic Paraparesis Patients.”J. Clin. Invest. 1994;94:1830-39.
Gao et al. “RecombinantSalmonella typhimuriumstrains that invade nonphagocytic cells are resistant to recognition by antigen-specific cytotoxic T lymphocytes.”Infect Immun. Sep. 1992;60(9):3780-9.
Glenn et al. “Skin immunization made possible by cholera toxin.”Nature. Feb. 26, 1998;391(6670):851.
Gnjatic et al. “Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules.”Eur. J. Immunol. 1995;25:1638-42.
Gura “Systems for identifying new drugs are often faulty.”Science. Nov. 7, 1997;278(5340):1041-2.
Hartwell et al. “Integrating genetic approaches into the discovery of anticancer drugs.”Science. Nov. 7, 1997;278(5340):1064-8.
Head et al. “Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function.”J Biol Chem. 1991;266(6):3617-21.
Heemels et al. “Generation, translocation, and presentation of MHC class I-restricted peptides.”Annu Rev Biochem. 1995;64:463-91.
Huang et al. “Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.”Science. May 13, 1994;264(5161):961-5.
Hui et al. “An isoform of the Golgi t-SNARE, syntaxin 5, with an endoplasmic reticulum retrieval signal.”Mol Biol Cell. Sep. 1997;8(9):1777-87.
Jain “Barriers to drug delivery in solid tumors.”Sci Am. Jul. 1994;271(1):58-65.
Johannes et al. “Retrograde Transport of KDEL-bearing B-fragment of Shiga Toxin.”J. of Biological Chemistry1997;272(31):19554-19561.
Johannes et al. “Shiga toxin as a tool to study retrograde transport.”Molecular Biology of the Cell1996;7(Supp.):75a (Annual Meeting of the 6thInternational Congress of Cell Biology and the 36thAmerican Society for Cell Biology, San Francisco, California).
Kavanaugh et al. “Immunologic dysfunction in cancer.”Hematol Oncol Clin North Am. Aug. 1996;10(4):927-51.
Kawakami et al. “Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes.”J. Exp. Med. 1994;180:347-52.
Ke et al. “Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.”Eur J Immunol. Feb. 1995;25(2):549-53.
Kim et al. “Dynamic Measurement of the pH of the Golgi Complex in Living Cells Using Retrograde Transport of the Verotoxin Receptor.”J. Cell Biol. 1996;134(6):1387-99.
Kimmel et al. “In vitro drug sensitivity testing in human gliomas.”J Neurosurg. Feb. 1987;66(2):161-71.
Kovacsovics-Bankowski et al. “Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.”Proc Natl Acad Sci U S A. Jun. 1, 1993;90(11):4942-6.
Kurts et al. “Constitutive class I-restricted exogenous presentation of self antigens in vivo.”J Exp Med. Sep. 1, 1996;184(3):923-30.
Lamb &#x
Goud Bruno
Johannes Ludger
Axelrod Nancy J.
Gollin Michael A.
Insem-Transfert
Universite Pierre Et Marie Curie (UPMC)
Venable LLP
LandOfFree
Chimeric polypeptide comprising the fragment B of shiga... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric polypeptide comprising the fragment B of shiga..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric polypeptide comprising the fragment B of shiga... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4137664